(Q38106616)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Michael D Wiese

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

T M Polasek

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

13 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

376-382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23670120%20AND%20SRC:MED&resulttype=core&format=json

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Personalized medicine: potential, barriers and contemporary issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Interpretation of random effects meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Random-effects meta-analyses are not always conservative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Meta-analysis of individual participant data: rationale, conduct, and reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Systematic reviews of evaluations of prognostic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Individual participant data meta-analysis of prognostic factor studies: state of the art?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Ten steps towards improving prognosis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Addressing the challenges of the clinical application of pharmacogenetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Pharmacogenomics, evidence, and the role of payers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Paraoxonase-1 is a major determinant of clopidogrel efficacy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Genetic substudy of the PLATO trial – Authors' reply

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021

What is clinical utility and why should we care?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.100

7 January 2021